Multiple faces of fibroblast growth factor-23

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 4, 2016, Pages 333-342

  Han, Xiaobin ^a   Quarles, L Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

chronic kidney disease; hypophosphatemia; inflammation; innate immunity; renin angiotensin system; Vitamin D metabolism; Klotho

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; VITAMIN D; ANGIOTENSIN CONVERTING ENZYME 2; BETA GLUCURONIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; FIBROBLAST GROWTH FACTOR; MINERAL; PHOSPHATE; SODIUM;

ADVERSE OUTCOME; BONE METABOLISM; CARDIOVASCULAR SYSTEM; GENETIC DISORDER; HEMODYNAMICS; HUMAN; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MINERAL METABOLISM; NONHUMAN; PARACRINE SIGNALING; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BONE; HEART LEFT VENTRICLE HYPERTROPHY; HOMEOSTASIS; HYPERTENSION; IMMUNOLOGY; KIDNEY; METABOLISM; OSTEOCYTE; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HOMEOSTASIS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNITY, INNATE; KIDNEY; MINERALS; OSTEOCYTES; PEPTIDYL-DIPEPTIDASE A; PHOSPHATES; SIGNAL TRANSDUCTION; SODIUM; VITAMIN D;

EID: 84969920152     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000240     Document Type: Review

References (110)

1. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 2010; 342:1-11.
2. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277:494-498.
3. Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008; 237:18-27.
4. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. {beta}Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol (Baltimore, Md) 2008; 22:1006-1014.
5. Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. J Bone Miner Res 2011; 26:1680-1683.
6. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285:E1-E9.
7. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 2003; 112:642-646.
8. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18:1637-1647.
9. Andersen IA, Huntley BK, Sandberg SS, et al. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant 2015; doi: 10. 1093/ndt/gfv398. [Epub ahead of print]
10. Leifheit-Nestler M, Grosse Siemer R, Flasbart K, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant 2015; doi: 10. 1093/ndt/gfv421. [Epub ahead of print]
11. Lang F, Foller M. Enigmatic Cassandra: renal FGF23 formation in polycystic kidney disease. Kid Int 2014; 85:1260-1262.
12. Spichtig D, Zhang H, Mohebbi N, et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kid Int 2014; 85:1340-1350.
13. Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nature reviews. Drug Discov 2016; 15:51-69.
14. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab 2015; 26:22-29.
15. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774.
16. Yu X, Ibrahimi OA, Goetz R, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146:4647-4656.
17. Li SA, Watanabe M, Yamada H, et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004; 29:91-99.
18. Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies demonstrate the physiological role and structural features of FGF23. J Bone Miner Res 2008; 23:1509-1518.
19. Lim K, Groen A, Molostvov G, et al. alpha-Klotho expression in human tissues. J Clin Endocrinol Metab 2015; 100:E1308-E1318.
20. Six I, Okazaki H, Gross P, et al. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS One 2014; 9:e93423.
21. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51.
22. Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klothodependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009; 23:433-441.
23. Tomiyama K, Maeda R, Urakawa I, et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA 2010; 107:1666-1671.
24. Lindberg K, Amin R, Moe OW, et al. The kidney is the principal organ mediating Klotho effects. J Am Soc Nephrol 2014; 25:2169-2175.
25. Samms RJ, Cheng CC, Kharitonenkov A, et al. Overexpression of b-Klotho in adipose tissue sensitizes male mice to endogenous FGF21 and provides protection from diet-induced obesity. Endocrinology 2016; 157:1467-1480.
26. Doi S, Zou Y, Togao O, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286:8655-8665.
27. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309:1829-1833.
28. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kid Int 2001; 60:2079-2086.
29. Yamamoto H, Ramos-Molina B, Lick AN, et al. Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. Bone 2016; 84:120-130.
30. Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012; 8:276-286.
31. Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278:37419-37426.
32. Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291:E38-E49.
33. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310-1315.
34. Martin A, Liu S, David V, et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. Faseb J 2011; 25:2551-2562.
35. Harmey D, Hessle L, Narisawa S, et al. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164:1199-1209.
36. Tagliabracci VS, Engel JL, Wiley SE, et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 2014; 111:5520-5525.
37. Zutt M, Strutz F, Happle R, et al. Schimmelpenning-Feuerstein-Mims syndrome with hypophosphatemic rickets. Dermatology 2003; 207:72-76.
38. Xiao Z, Huang J, Cao L, et al. Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS One 2014; 9:e104154.
39. Han X, Xiao Z, Quarles LD. Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem 2015; 290:20101.
40. Xiao L, Esliger A, Hurley MM. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Min Res 2013; 28:35-45.
41. Leaf DE, Pereira RC, Bazari H, Juppner H. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab 2013; 98:887-891.
42. Lee EK, Martinez MC, Blakely K, et al. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia? Med Hypothes 2014; 83:482-487.
43. Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96:365-408.
44. Barthel TK, Mathern DR, Whitfield GK, et al. 1, 25-Dihydroxyvitamin D3/VDRmediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 2007; 103:381-388.
45. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17:1305-1315.
46. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280:2543-2549.
47. Masuyama R, Stockmans I, Torrekens S, et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006; 116:3150-3159.
48. Yu X, Sabbagh Y, Davis SI, et al. Genetic dissection of phosphate-and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005; 36:971-977.
49. Saini RK, Kaneko I, Jurutka PW, et al. 1, 25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int 2013; 92:339-353.
50. Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012; 8:276-286.
51. Brown WW, Juppner H, Langman CB, et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 2009; 94:17-20.
52. Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18:2683-2688.
53. Sato T, Tominaga Y, Ueki T, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44:481-487.
54. Tebben PJ, Singh RJ, Clarke BL, Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha, 25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 2004; 79:1508-1513.
55. Saji F, Shigematsu T, Sakaguchi T, et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha}, 25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010; 299:F1212-F1217.
56. David V, Dai B, Martin A, et al. Calcium regulates FGF-23 expression in bone. Endocrinology 2013; 154:4469-4482.
57. Samadfam R, Richard C, Nguyen-Yamamoto L, et al. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009; 150:4835-4845.
58. Lee YW, Terranova C, Birkaya B, et al. A novel nuclear FGF receptor-1 partnership with retinoid and Nur receptors during developmental gene programming of embryonic stem cells. J Cell Biochem 2012; 113:2920-2936.
59. Meir T, Durlacher K, Pan Z, et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kid Int 2014; 86:1106-1115.
60. Roforth MM, Liu G, Khosla S, Monroe DG. Examination of nuclear receptor expression in osteoblasts reveals Rorbeta as an important regulator of osteogenesis. J Bone Miner Res 2012; 27:891-901.
61. Imai Y, Youn MY, Inoue K, et al. Nuclear receptors in bone physiology and diseases. Physiol Rev 2013; 93:481-523.
62. Achiron A, Feldman A, Gurevich M. Characterization of multiple sclerosis traits: nuclear receptors (NR) impaired apoptosis pathway and the role of 1-alpha 25-dihydroxyvitamin D3. J Neurol Sci 2011; 311:9-14.
63. Kaneko I, Saini RK, Griffin KP, et al. FGF23 gene regulation by 1, 25-dihydroxyvitamin D: opposing effects in adipocytes and osteocytes. J Endocrinol 2015; 226:155-166.
64. Schoppet M, Hofbauer LC, Brinskelle-Schmal N, et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab 2012; 97:E575-E583.
65. Zhang B, Yan J, Schmidt S, et al. Lithium-sensitive store-operated Ca2R entry in the regulation of FGF23 release. Neurosignals 2015; 23:34-48.
66. Xiao Z, Cao L, Liang Y, et al. Osteoblast-specific deletion of Pkd2 leads to low-turnover osteopenia and reduced bone marrow adiposity. PLoS One 2014; 9:e114198.
67. Arai-Nunota N, Mizobuchi M, Ogata H, et al. Intravenous phosphate loading increases fibroblast growth factor 23 in uremic rats. PLoS One 2014; 9:e91096.
68. Zhang S, Gillihan R, He N, et al. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. Kid Int 2013; 84:713-721.
69. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91:3144-3149.
70. Perwad F, Azam N, Zhang MY, et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1, 25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; 146:5358-5364.
71. Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015; 22:1020-1032.
72. Schlingmann KP, Ruminska J, Kaufmann M, et al. Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J Am Soc Nephrol 2016; 27:604-614.
73. Segawa H, Onitsuka A, Furutani J, et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol 2009; 297:F671-F678.
74. Alshayeb H, Showkat A, Wall BM, et al. Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. J Clin Endocrinol Metab 2014; 99:E1830-E1837.
75. Barragan M, Good M, Kolls JK. Regulation of dendritic cell function by vitamin D. Nutrients 2015; 7:8127-8151.
76. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diab Endocrinol 2014; 2:76-89.
77. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014; 348:g1903.
78. Munoz Mendoza J, Isakova T, Ricardo AC, et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012; 7:1155-1162.
79. Mendoza JM, Isakova T, Ricardo AC, et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 2012; 7:1155-1162.
80. Kubin T, Poling J, Kostin S, et al. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell 2011; 9:420-432.
81. Masuda Y, Ohta H, Morita Y, et al. Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice. Biol Pharm Bull 2015; 38:687-693.
82. Dai B, David V, Martin A, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012; 7:e44161.
83. Chonchol M, Greene T, Zhang Y, et al. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol 2016; 27:227-237
84. Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 2016; 126:962-974.
85. Ito N, Wijenayaka AR, Prideaux M, et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol 2015; 399:208-218.
86. Han X, Li L, Yang J, et al. Counter-regulatory paracrine actions of FGF-23 and 1, 25(OH)2 D in macrophages. FEBS Lett 2016; 590:53-67.
87. Wang TJ. Vitamin D and cardiovascular disease. Ann Rev Med 2016; 67:261-272.
88. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117:503-511.
89. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New Engl J Med 2003; 349:446-456.
90. Li YC, Kong J, Wei M, et al. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
91. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103:521-524.
92. Chen S, Law CS, Grigsby CL, et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 2011; 124:1838-1847.
93. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307:674-684.
94. Durup D, Jorgensen HL, Christensen J, et al. A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: the CopD study. J Clin Endocrinol Metab 2015; 100:2339-2346.
95. Ralph R, Peter JV, Chrispal A, et al. Supraphysiological 25-hydroxy vitamin D3 level at admission is associated with illness severity and mortality in critically ill patients. J Bone Min Metab 2015; 33:239-243.
96. Andrukhova O, Slavic S, Smorodchenko A, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014; 6:744-759.
97. Nehgme R, Fahey JT, Smith C, Carpenter TO. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1997; 82:2450-2454.
98. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011; 22:1603-1609.
99. Xie J, Cha SK, An SW, et al. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 2012; 3:1238.
100. Xie J, Yoon J, An SW, et al. Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 2015; 26:1150-1160.
101. Wohlfahrt P, Melenovsky V, Kotrc M, et al. Association of fibroblast growth factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure. JACC Heart failure 2015; 3:829-839.
102. Poling J, Gajawada P, Richter M, et al. Therapeutic targeting of the oncostatin Mreceptor-beta prevents inflammatory heart failure. Basic Res Cardiol 2014; 109:396.
103. Richter M, Lautze HJ, Walther T, et al. The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J Heart Lung Transplant 2015; 34:1211-1214.
104. House SL, House BE, Glascock B, et al. Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. Mol Cell Pharmacol 2010; 2:143-154.
105. Pellieux C, Foletti A, Peduto G, et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 2001; 108:1843-1851.
106. Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 2011; 6:e18398.
107. Su N, Jin M, Chen L. Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res 2014; 2:14003.
108. Turkington RC, Longley DB, Allen WL, et al. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis 2014; 5:e1046.
109. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochimica et biophysica acta 2012; 1823:850-860.
110. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35:1192-1199.